Navigation Links
Sweden to Receive Scandinavia's First TomoTherapy System : Lund University Hospital to Offer Swedish Cancer Patients the Most Advanced Image-Guided Radiation Therapy Treatments
Date:7/31/2008

TomoTherapy Incorporated (NASDAQ: TOMO) announced today that it has extended its reach in Europe with the first TomoTherapy HiArt treatment system set to be installed in Scandinavia, at Lund University Hospital in Sweden.

MADISON, Wis. (Business Wire EON) July 31, 2008 -- Jef Van Dam, general manager of TomoTherapyEMEA, said, "TomoTherapy is extremely pleased to partner with Lund University Hospital. This marks our entry into the Swedish market with a prestigious institution that pioneered the use of many technological advances in Scandinavia andEurope. We look forward to delivering the advanced HiArt system to continue that tradition."

Lund University Hospital conducted an extensive investigation of all commercially available intensity-modulated radiation therapy (IMRT) systems, including arc-based options on conventional platforms, before making the decision to purchase the TomoTherapy HiArt system.

Charlott Wictor, strategic purchaser of medical equipment for the Skane region in Sweden, championed TomoTherapy and helped the purchase become reality: "This was a great team effort working with the Lund medical and physics experts to bring this advanced technology to our Swedish patients. TomoTherapy was clearly the best choice from both a high technology and economic standpoint."

Jacob Engellau, M.D., Ph.D., head of radiation oncology at Lund University Hospital, believes TomoTherapy will have a great impact on patient treatments. "As a large center treating 2500 new patients yearly, we are dependent on high up-time and clinical reliability. The established and clinically well-implemented TomoTherapy HiArt was the only system that could meet the demands of our clinic."

Tommy Kns, Ph.D., associate professor and head of radiation physics at Lund University Hospital, was also an important decision maker in the process. "We think TomoTherapy is the most advanced image-guided system for radiotherapy with an integrated functionality for imaging and localisation of the target volume. It also produces the most advantageous dose distributions for IMRT," according to Kns.

Added Engellau, "With the HiArt system, we see obvious clinical advantages for treating complex radiation target volumes, multiple targets and targets requiring a high radiation dose with close proximity to healthy organs. Conventional 3D conformal radiation or IMRT can treat some but not all of these case types. If the cases can be attempted, we believe the results would be less conformal, less accurate and with much longer treatment times than with TomoTherapy."

While TomoTherapy will be used to treat a wide array of cancers, the clinical experts at Lund plan to focus on anal, rectal, cervical, stomach and esophageal cancers. They will also be using the HiArt system for stereotactic radiosurgery treatments and see greater possibilities for clinical trials involving simultaneously integrated boost (SIB) with or without dose escalation.

Lund University Hospital plans to install the TomoTherapy HiArt system later this year.

About TomoTherapy Incorporated

TomoTherapy Incorporated has developed, markets and sells the TomoTherapy HiArt treatment system, an advanced radiation therapy system for the treatment of a wide variety of cancers. The HiArt treatment system combines integrated CT imaging with conformal radiation therapy to deliver sophisticated radiation treatments with speed and precision while reducing radiation exposure to surrounding healthy tissue. The company's stock is traded on the NASDAQ Global Select Market under the symbol TOMO. To learn more about TomoTherapy, please visit TomoTherapy.com.

Forward-Looking Statements

Statements in this release regarding future events, expectations and other similar matters, including but not limited to statements using the terms "look forward to" or "will" constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements contained in this press release are subject to risks and uncertainties that could cause actual results to differ materially from those anticipated, including but not limited to factors such as our ability to integrate acquired assets, ability to protect intellectual property, risks of interruption due to events beyond the company's control, and the other risks listed from time to time in TomoTherapy's filings with the U.S. Securities and Exchange Commission, which by this reference are incorporated herein. These forward-looking statements represent TomoTherapy's judgments as of the date of this press release. TomoTherapy assumes no obligation to update or revise the forward-looking statements in this release because of new information, future events or otherwise.

2008 TomoTherapy Incorporated. All rights reserved.TomoTherapy, the TomoTherapy logo and HiArt are among trademarks, service marks or registered trademarks of TomoTherapy Incorporated.

Read the full story at http://www.prweb.com/releases/tomotherapy/lund_university/prweb1167744.htm


'/>"/>
Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Nephros Exhibits at the XLV ERA-EDTA Congress in Stockholm, Sweden, May 10-13, 2008
2. The Feinstein to collaborate with Swedens Karolinska Institute
3. Medco Partners to Develop Patient-Safety System for Prescription Drugs in Sweden
4. University of South Florida receives new multimillion award to assess juvenile diabetes treatments
5. Lupin Receives USFDA Approval for Divalproex Sodium Delayed-Release Tablets
6. Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA Approval for Simvastatin Tablets
7. Go Healthy Receives Letter of Recognition From the Texas Chiropractic Association
8. Eagle Ventures Subsidiary Hydrate2O Receives 2008 Top Gear of the Year Award From ShapeYou.com
9. Escalon(R) Receives FDA 510(k) Clearance to Market the LIASYS(TM) Clinical Chemistry and Immunoturbidimetric Analyzer
10. French Agency Receives 10 Million Dollar Grant From the Bill & Melinda Gates Foundation to Support the Establishment of National Vaccine Advisory Committees in Africa and Asia
11. Pandemic research receives $1.6M funding boost
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
 Sweden to Receive Scandinavia's First TomoTherapy System :  Lund University Hospital to Offer Swedish Cancer Patients the Most Advanced Image-Guided Radiation Therapy Treatments 
(Date:6/25/2016)... ... ... Bruton Memorial Library on June 21 due to a possible lice infestation, as reported by ... lice: the parasite’s ability to live away from a human host, and to infest common ... the event that lice have simply gotten out of control. , As lice are a ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... As a ... Magna Cum Laude and his M.D from the David Geffen School of Medicine at ... returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars ...
(Date:6/25/2016)... , ... June 25, 2016 , ... Conventional wisdom preaches ... success. In terms of the latter, setting the bar too high can result in ... than just slow progress toward their goal. , Research from PsychTests.com ...
(Date:6/24/2016)... ... , ... June 19, 2016 is World Sickle Cell Observance Day. In an ... of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a ... Cell Disease (SCD) is a disorder of the red blood cells, which can cause ...
(Date:6/24/2016)... ... 2016 , ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida ... their peers for this recognition are considered among the top 2 percent of lawyers ... as members of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016 The Academy of Managed Care ... that would allow biopharmaceutical companies to more easily ... make formulary and coverage decisions, a move that addresses ... medicines. The recommendations address restrictions in the ... the drug label, a prohibition that hinders decision makers ...
(Date:6/24/2016)... SAN CLEMENTE, Calif. , June 24, 2016  American ... function testing company, is now able to perform sophisticated lung assessments ... ndd Medical Technologies , Inc. Patients are no ...  Thanks to ndd,s EasyOne PRO ® , ARL patients like Jeanne ... needed testing done in the comfort of her own home. ...
(Date:6/24/2016)... , June 24, 2016 According ... by Type (Standard Pen Needles, Safety Pen Needles), Needle ... GLP-1, Growth Hormone), Mode of Purchase (Retail, Non-Retail) - ... This report studies the market for the forecast period ... reach USD 2.81 Billion by 2021 from USD 1.65 ...
Breaking Medicine Technology: